The Keytruda injunction and the risk of enforcing too soon

Halozyme’s injunction against the subcutaneous formulation of Keytruda highlights the financial risks of enforcing patent rights while a judgment remains open to challenge. We explore the distinct liabilities that can arise from interim relief and enforcement pending appeal—and where specialist insurance may help manage the exposure.